This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up
Mechanism of Action  Safety & Tolerability

Menu

Close

Dosing Dosing Dosing Information Dose Adjustments Drug Interactions Efficacy & Trial Design Efficacy Efficacy Trial Design Safety & Tolerability Prescribing Information
Support & ResourcesSupport &
​​​​​​​Resources Materials Videos Frequently Asked Questions
PAXLOVID was well-tolerated in the EPIC-HR trial1

Comparable rates of adverse events were observed between PAXLOVID and placebo across a large, diverse trial in high-risk patients                   

 The most common adverse reactions reported during treatment with Paxlovid in the EPIC-HR trial were dysgeusia (4.6%), diarrhoea (3.0%), headache (1.2%) and vomiting (1.2%).1,2**Not serious adverse events and were resolved.1
PAXLOVID's safety profile in the EPIC-HR trial was comparable to that of placebo and it does not contain a boxed warning1,2


For more information about adverse reactions, see section 4.8 of the SmPC [here]
Reporting adverse events
Report suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in section 4.8 of the Summary of Product Characteristics [here] . 

Reporting suspected adverse reactions directly to [email protected] or contact Pfizer at 1800 633 363.
EXPLORE MORESupport and resources for you and patients

Access information about resources, including videos, brochures, and guides, to learn more and support your patients.

 ResourcesLoading Frequently Asked Questions Loading Drug Interactions

Before prescribing PAXLOVID, identify any medicinal products your patient may be taking, as some may be contraindicated for concomitant use or may create potentially significant drug interactions. Then, easily search for drug interactions by active substance name or keywords. 

 Search LoadingReferences:
  1. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19. N Engl J Med. 2022;386(15):1397-1408.
  2. PAXLOVID Summary of Product Characteristics. https://www.medicines.ie/medicines/paxlovid-150-mg-100-mg-film-coated-tablets-35210/spc (Accessed October 2023).
 
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.

Legal Category: S1A
Further information is available upon request

PP-PAX-IRL-0176. October 2023

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
 

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland Unlimited Company, The Watermarque Building, Ringsend Road, Dublin 4, Dublin, Ireland, D04 K7N3.  Registered in the Republic of Ireland No. 127002. Directors: D. Mangone (Managing), O. Gavan, D. Kennedy. Company Secretary: M.Byrne.  

 

Copyright © 2024 Pfizer Limited. All rights reserved.
 

PP-UNP-IRL-0832. October 2024
For Healthcare Professionals in the Republic of Ireland *

The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

I confirm that I am a healthcare professional* resident in the Republic of Ireland.

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland Unlimited Company.

*The IPHA Code definition of a healthcare professional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

Terms of use

PP-UNP-IRL-0832. October 2024

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.


PP-UNP-IRL-0832. October 2024